Alendronate Sodium NDC 70954-264

NDC codes

FDA NDC Directory

Product NDC (as listed)70954-264Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70954-0264Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70954-264-10	70954026410	4 BOTTLE in 1 CARTON (70954-264-10) / 75 mL in 1 BOTTLEMarketed from May 24, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alendronate Sodium
Generic name (nonproprietary): alendronate sodium
Active ingredients: Alendronate sodium — 70 mg/75mL
Dosage form: Solution
Route: Oral
Labeler: ANI Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214512
Marketing start: May 24, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 70954-264_844cce5a-3714-4394-be02-a25a6255330aSPL ID 844cce5a-3714-4394-be02-a25a6255330aSPL set ID 81589178-10c9-4806-91eb-54e638d35b8dRxCUI 904447UNII 2UY4M2U3RAUPC 0370954264101
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470954026410 followed by a unit qualifier and the quantity

Package 70954-0264-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 29, 2025.

Indications (excerpt from the label)

Alendronate Sodium Oral Solution is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women (1.1) Treatment to increase bone mass in men with osteoporosis (1.3) Limitations of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. (1.6) 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, alendronate increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures) [ see Clinical Studies (14.1)…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)